Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Hematologic Neoplasms 3Primary Myelofibrosis 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Myeloproliferative Disorders 2Myelodysplastic Syndromes 2Lymphoma, Non-Hodgkin 2Leukemia, Myeloid, Chronic-Phase 2Leukemia, Myeloid, Acute 2Leukemia, Myeloid, Accelerated Phase 2Leukemia, Lymphocytic, Chronic, B-Cell 2Hodgkin Disease 2Multiple Myeloma 1Cytomegalovirus Infections 1

Interventions

Valganciclovir 2letermovir 1Valacyclovir 1Therapeutics 1Polymerase Chain Reaction 1Ganciclovir 1Foscarnet 1Flow Cytometry 1Cell Count 1Blood Specimen Collection 1Antiviral Agents 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cytomegalovirus Infections × letermovir × 1 year × Clear all
NCT04017962 2025-08-11

A Study of the Drug Letermovir (LTV) as Prevention for Recurrent of Cytomegalovirus (CMV) Infection

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
102 enrolled 13 charts

Cytomegalovirus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡